文献速递艾滋病与性传播感染

ICONA队列中用于HIV治疗的长效注射抗逆转录病毒药物:医生和护士的观点

Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

在意大利ICONA网络的38个中心(62%)对104名感染科医生和77名护士进行横断面在线调查,评估长效注射卡博特韦/利匹韦林(LAI CAB/RPV)的实施现状与障碍。研究时点仅4.5%的HIV感染者开始使用该方案,实施水平低且随中心规模差异大;AIM、IAM、FIM平均分均为16.0。

要点

  • 38个ICONA中心完成调查,研究时点4.5%的HIV感染者开始使用LAI CAB/RPV。
  • 接诊超过1000例HIV感染者的中心实施流程应用率达95%,高于其他中心(P=0.009)。
  • AIM、IAM、FIM平均分均为16.0,实施障碍在不同规模中心间无显著差异。

核心结论

  • LAI CAB/RPV实施水平低,且随中心规模呈现很大变异性。
  • 作者认为应设计量身定制且针对各中心的干预措施以解决障碍并优化长效治疗实施。

研究设计与样本

  • 横断面在线调查,对象为意大利ICONA网络的感染科医生和护士。
  • 61个ICONA中心中38个(62%)完成调查,其中57.9%为学术中心、42.1%为医院中心。
  • 应答者共104名感染科医生(57.4%)和77名护士(42.5%)。
  • 使用三种经过验证的各含4个条目的量表:干预可接受性测量(AIM)、干预适当性测量(IAM)和干预可行性测量(FIM)。

主要发现

  • 研究时点38个中心接诊的HIV感染者中4.5%已开始使用LAI CAB/RPV。
  • 接诊超过1000例HIV感染者的中心报告LA实施流程应用率达95%,高于其他中心(P=0.009)。
  • AIM平均分为16.0(标准差3.3),IAM平均分为16.0(标准差3.0),FIM平均分为16.0(标准差2.9)。
  • AIM与已开始LAI CAB/RPV的HIV感染者数量(25-50例 vs 少于25例)呈线性相关(相关系数b=2.57,95%CI 0.91-4.60,P=0.004)。
  • AIM与学术中心 vs 医院中心相关(b=-1.59,95%CI -2.76-0.110044,P=0.007),与未对员工进行初步系统评估相关(b=-1.98,95%CI -3.31-0.65,P=0.004)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Implementation level of long-acting injectable agents cabotegravir/rilpivirine (LAI CAB/RPV) for human immunodeficiency virus (HIV) treatment in Italy is still not known. The aim of this study is to identify the status of implementation of LAI CAB-RPV and its barriers. MATERIALS AND METHODS: A cross-sectional online survey was conducted among infectious diseases (ID) physicians and nurses belonging to the ICONA network in Italy. Three validate 4-items measures were used: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM). RESULTS: Out of 61 ICONA centres, 38 (62%) completed the survey: 57.9% were academic centres, 42.1% were hospital-based. In total, 104 respondents were ID physicians (57.4%), 77 were nurses (42.5%); 4.5% of all PWH followed at the 38 centres started LAI CAB/RPV at time of study. Centres taking care of >1000 PWH reported 95% application of procedures for LA implementation, higher than other centres (P = 0.009). Mean score of AIM was (16.0, standard deviation, SD, 3.3), of IAM (16.0, SD 3.0) and FIM (16.0, SD 2.9). A linear correlation was found between AIM and the number of people with HIV who started LAI CAB/RPV (25-50 versus <25, coefficient of correlation [b] 2.57, 95%CI 0.91-4.60, P = 0.004), academic versus hospital-based centres (b -1.59, 95%CI -2.76-0.110044, P = 0.007) and the absence of preliminary systematic assessment of staff (b -1.98, 95%CI -3.31-0.65, P = 0.004). Implementation barriers were not significantly different according to the number of PWH/centre. CONCLUSIONS: LAI CAB/RPV implementation was low, with a great variability according to centre size. Tailored and centre-specific interventions to address barriers and to optimize the LA treatment implementation should be designed.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Cingolani A, Tavelli A, De Benedittis S, et al. Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view. J Antimicrob Chemother. 2024. PMID: 39140512. doi:10.1093/jac/dkae273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。